Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Chagas Disease
- Main trialPhase 2
- “This study is to investigate the ability of LXE408 to clear or reduce the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without severe organ dysfunction.”In the company’s words, NCT06632600 on ClinicalTrials.gov
Other drugs for Chagas Disease
- BenznidazoleInsud Pharma · Phase 3
- BenznidazoleLaboratorio Elea Phoenix S.A. · Phase 3
Coming up1
- 22 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 22 Jul 2027 | A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. | |
| Phase 1Completed | 27 Sep 2021 | A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026